Abstract:

　Vascularized composite allotransplantation (VCA) is an effective treatment to restore functional and aesthetic

outcomes for patients suffering from devastating composite tissue loss. Life-long immunosuppression administration is usually

mandatory for VCA patients to avoid immune rejection. However, the subsequent adverse effects would impair life quality or even

cause death. Local delivery of controlled-release immunosuppressants is advantageous on maintaining a high level of medication

and decreasing organ toxicities. In this paper, the biomaterial-based controlled-release systems in VCA were reviewed.

Key words:

Vascularized composite allotransplantation, 　Immunosuppressive therapy, 　Controlled-release system, 　

Biomaterial